Patrys Acquires Novel Assets from Yale University
Released
Released
Announcement PDF
ASX & Media Release
Patrys Acquires License to Novel NucleusPenetrating Antibody Assets Developed at Yale
University
Acquisition provides Patrys with license rights to a portfolio of novel anti-DNA antibodies
that penetrate into cell nuclei
Novel pre-clinical oncology assets and platform have multiple potential applications to treat
a range of cancers
Melbourne, Australia; 29 March, 2016: Patrys Limited (ASX: PAB) has acquired a worldwide license
to develop and commercialise as anti-cancer agents a portfolio of pre-clinical novel anti-DNA
antibodies and antibody fragments/variants discovered at Yale University. The antibodies have the
unusual ability to penetrate into cancer cell nuclei and inhibit DNA repair mechanisms, and have
potential application as stand-alone therapies and as adjuncts to augment existing therapies or to
help overcome resistance associated with DNA repair mechanisms.
Patrys has acquired the license for the novel anti-DNA antibody platform through a scrip acquisition,
of Nucleus Therapeutics Pty Ltd (Nucleus) in a tranched transaction with a value of up to A$720,000.
Based on the current number of shares on issue, and successful completion of a range of milestones
that trigger the issue of Patrys shares to satisfy tranche payments, the vendors, including Yale
University, will ultimately own approximately 14.36% of Patrys’ issued capital.
The lead candidates licensed from Yale are autoantibodies known as 3E10 (Deoxymab) and 5C6.
These novel antibodies have the capacity to penetrate cancer cell nuclei, damage DNA, inhibit DNA
repair, and kill DNA repair-deficient cancer cells. Both Deoxymab and 5C6 when used as single
agents are selectively toxic to cancer cells with DNA repair deficiencies such as those with mutations
in the BRCA2 and PTEN genes. The mechanisms of action of both Deoxymab and 5C6 have possible
advantages over poly ADP ribose polymerase (PARP) inhibitors as these antibodies are able to inhibit
both single and double-stranded DNA repair pathways and cause accumulation of DNA damage in
cancer cells. This suggests potential utility in a range of cancers, including some rare diseases like
glioblastoma.
As well as showing single agent potential, the antibodies have the ability to sensitise cancer cells to
radiation and chemotherapy and interfere with cancer cells’ ability to sustain themselves through
DNA repair.
Deoxymab and 5C6 are the subject of three patent applications which have been lodged by Yale
University, the University of California Los Angeles and the United States Department of Veterans
Affairs. Protection is being pursued in major markets such as Europe, Japan and the US. These
1
patent applications cover both the use of Deoxymab and fragments/variants thereof to treat cancer,
and protection will extend to 2035.
“We are delighted to have finalised the acquisition and to be the licensee of these exciting new
assets” said Dr James Campbell, Patrys’ Chief Executive Officer. “Our team has evaluated numerous
potential assets from around the globe, and we feel confident that these assets offer a favourable
risk/reward profile for our shareholders. This acquisition elevates and expands Patrys’ oncology
pipeline beyond IgM technologies, and gives Patrys a strong position in a new field of immunooncology.”
Patrys will initiate and manage pre-clinical studies of a number of lead candidates to guide an
eventual clinical development strategy for the new assets, working closely with the inventors from
Yale University.
Inventor of Deoxymab and Yale radiation oncologist, Dr. James Hansen, added: “We are very excited
to be working with the Patrys team on a shared vision of building a world-class oncology franchise,
which integrates our anti-DNA antibodies with Patrys’ strengths in product development.”
The transaction has three potential tranches, with each tranche being settled in Patrys shares based
on the volume weighted average price (VWAP) of Patrys shares for the 7 days prior to the
completion of a milestone. The first milestone has been achieved, and requires the issue of Patrys
shares to satisfy the first tranche payment of A$360,000 to the vendors. The second tranche will be
triggered by the granting of specified patents associated with the Yale technology, and will result in
the issue of Patrys shares to satisfy the second tranche payment of A$180,000. The final tranche,
triggered upon the first dosing of a patient in a phase 1 clinical trial will also result in the issue of
Patrys shares to satisfy the final tranche payment of A$180,000.
For the purposes of ASX Listing Rule 3.10.3, Patrys advises that it proposes to issue a maximum of
50,033,425 fully paid ordinary shares (ranking equally with ordinary shares on issue) at a price of 0.7
cents per share to Nucleus shareholders in connection with the first tranche of the transaction
described above. No shareholder approval will be sought in relation to this proposed issue. The
terms of the Yale license agreement are confidential, but include standard obligations including an
agreed development plan, milestones and a sliding scale of annual net royalties on eventual sales.
-EndsFor further information, please contact:
Patrys Limited:
James Campbell
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com
Patrys IR:
Kyahn Williamson
Buchan Consulting
P: +61 3 9866 4722
kwilliamson@buchanwe.com.au
2
Patrys Media:
Kellie Stanborough
Buchan Consulting
P: +61 3 9866 4722
kstanborough@buchanwe.com.au
About Patrys Limited:
Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of
different cancers. Patrys has a pipeline of anti-cancer antibodies that enable both internal development and partnering
opportunities. More information can be found at www.patrys.com
About BRCA2 and PTEN Gene Mutations:
Certain types of cancers occur when DNA repair goes awry because of inherited gene mutations. BRCA2 is a tumour
suppressor that, when damaged or deficient, can lead to malignancies such as breast, ovarian, pancreatic, and prostate
cancers while PTEN mutations are related to breast, brain gliomas and astrocytomas, head and neck carcinoma,
endometrial and thyroid tumour development.
About 3E10 and 5C6 anti-DNA antibodies:
A nuclear-penetrating lupus anti-DNA autoantibody 3E10 (Deoxymab) is novel cancer therapy that has the capacity to
penetrate cancer cell nuclei, inhibit DNA repair, and kill DNA repair-deficient cancer cells. The antibody preferentially
localises to tumours and has the ability to sensitise cancer cells to radiation and chemotherapy and interfere with their
ability to sustain themselves through DNA repair. Furthermore, 3E10 when used alone can selectively kill cancer cells with
DNA repair deficiencies such as those with mutations in the BRCA2 and PTEN gene. These characteristics of 3E10 open up
new possibilities for treating BRCA2 and PTEN-related cancers. Yale University has also found that 5C6, an anti-DNA
autoantibody that can penetrate cells, has a toxic effect on BRCA2-deficient cells in colon cancer.
Recent publications for this work can be found at the following websites:
http://cancerres.aacrjournals.org/content/75/11/2285.long
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496662/
http://www.nature.com/articles/srep05958
3
Share your feedback
Discover